A QIP to develop trust-wide guideline for Parkinson’s patients while nil by mouth to improve confidence in clinicians.

Abstract ID
3742
Authors' names
M. Rahman (1), D. Khan (1)
Author's provenances
Walsall Manor Hospital, Walsall Healthcare NHS Trust (1)
Abstract category
Abstract sub-category
Conditions

Abstract

Introduction: Parkinson's disease is a progressive neurological degeneration of certain cells (called dopaminergic cells) within a specific part of the brain (substantia nigra). (1) Withholding PD medication or a prolonged delay in administering PD medication can lead to an increase in care needs and increases the risk of neuroleptic malignant type syndromes, which can be fatal. (2).

Method: Prospective data was collected amongst doctors of different grades working in the Trust using Google forms.

Results: Baseline data was collected in January 2025. 88.9% responders managed PD patients in their daily practice; majority of them were foundation year doctors (83.3%). 55.6% of the responders did not feel confident in managing patients with PD who were nil by mouth. 72.2% of the responders are not aware of the local pathways to request a specialist review and the OOH support available. A Trust-wide Parkinson's Guidelines was then developed in reference to Parkinson’s patients who were nil by mouth or had swallowing difficulties; addressing all the concerned areas suggested in the baseline data collection. We then arranged two teaching sessions, first for the resident doctors in Geriatric Medicine department and a second session for Foundation doctors as they were identified as the target group of resident doctors during initial data collection. The second round of data collection was completed following these sessions. Following the sessions, we noted that the confidence level amongst responders significantly improved. We measured this on a rating scale of 1-5, with 83.3% responders reporting significant improvement in their levels of confidence managing PD patients who are NBM. 

Conclusion: Symptomatic treatment, focused on replacing dopamine, is crucial in optimising patient outcomes and quality of life. (2) Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.  (3) 

Comments

I would be keen to know whether the authors / hospital guidelines referenced the PDMedCalc guidelines, which is used by many hospitals across the UK.

Submitted by Alison.yarnall_25461 on

Permalink

Good work!

Spreading awareness among prescribers about PD medications and their timing, especially when patients are NBM and during out-of-hours, is really important for patient safety.

Submitted by tmadher.bawazi… on

Permalink

Thank you for the appreciation. We took this initiative after spending time on the surgical/orthopedic wards.

Submitted by daim5556_23259 on

In reply to by tmadher.bawazi…

Permalink